Human HSP90 alpha ELISA Kit (Colorimetric) Summary
Applications/Dilutions
Packaging, Storage & Formulations
Kit Components
- Human HSP90 alpha Standard lyophilized, 20 ng/mL upon reconstitution
- Adhesive Films
- Aluminium pouch(es) with a Microwell Plate coated with monoclonal antibody to human HSP90 alpha
- Biotin-Conjugate anti-human HSP90 alpha monoclonal antibody
- Assay Buffer Concentrate 20x (PBS with 1% Tween 20 and 10% BSA)
- Wash Buffer Concentrate 20x (PBS with 1% Tween 20)
- Substrate Solution (tetramethyl-benzidine)
- Streptavidin-HRP
- Sample Diluent
- Stop Solution (1M Phosphoric acid)
Alternate Names for Human HSP90 alpha ELISA Kit (Colorimetric)
- FLJ31884
- Heat shock 86 kDa
- heat shock 90kD protein 1, alpha
- heat shock 90kD protein 1, alpha-like 4
- heat shock 90kD protein, alpha-like 4
- heat shock 90kDa protein 1, alpha
- heat shock protein 90kDa alpha (cytosolic), class A member 1
- heat shock protein HSP 90-alpha
- HSP86
- Hsp89
- HSP89A
- HSP90 alpha
- Hsp90
- HSP90A
- HSP90AA1
- HSP90AHSP86
- HSP90N
- HSPC1
- HSPC1HSP 86
- HSPCA
- HSPCAHSP89A
- HSPCAL1
- HSPCAL4
- HSPN
- LAP2
- Renal carcinoma antigen NY-REN-38
Background
HSP90 alpha is a molecular chaperone that belongs to the heat shock protein 90 family predominantly known in helping in the refolding of misfolded proteins or their elimination in case of irreversible damage. The name is simply derived from the molecular weight roughly being 90 Kilo Daltons. There are two existing isoforms, Heat Shock Protein 90 alpha (HSP90a) and Heat Shock Protein 90 beta (HSP90B), with 76% homology. HSP90 is a very abundant continuously expressed protein also involved in non-stress related processes such as structural maintenance, cell cycle control and cell signalling. The protein contains three functional domains, the ATP-binding, protein binding and dimerizing domain all essential for the cytoprotecitve properties of HSP90.
HSP90 has emerged as a potential target for cancer therapy as many tumor cells such as non-small cell lung cancer, oesophageal squamous cell carcinoma, pancreatic carcinoma and malignant melanoma overexpress HSP90alpha. The activity of many oncogenic proteins depend on HSP90 and anti HSP90alpha drugs have become an exciting area in the search for cancer therapies and other diseases.
Limitations
product targets : (gamma)-secretase inhibitors